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Abstract
Background: This study aimed to compare efficacy and safety of test-adalimumab (CinnoRA®, CinnaGen, Iran) to
the innovator product (Humira®, AbbVie, USA) in adult patients with active rheumatoid arthritis (RA).
Methods: In this randomized, double-blind, active-controlled, non-inferiority trial, a total of 136 patients with
active RA were randomized to receive 40 mg subcutaneous injections of either CinnoRA® or Humira® every
other week, while receiving methotrexate (15 mg/week), folic acid (1 mg/day), and prednisolone (7.5 mg/day)
over a period of 24 weeks. Physical examinations, vital sign evaluations, and laboratory tests were conducted
in patients at baseline and at 12-week and 24-week visits. The primary endpoint in this study was the
proportion of patients achieving moderate and good disease activity score in 28 joints-erythrocyte
sedimentation rate (DAS28-ESR)-based European League Against Rheumatism (EULAR) response. The secondary
endpoints were the proportion of patients achieving American College of Rheumatology (ACR) criteria for
20% (ACR20), 50% (ACR50), and 70% (ACR70) responses along with the disability index of health assessment
questionnaire (HAQ), and safety.
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Results: Patients who were randomized to CinnoRA® or Humira® arms had comparable demographic information,
laboratory results, and disease characteristics at baseline. The proportion of patients achieving good and moderate
EULAR responses in the CinnoRA® group was non-inferior to the Humira® group at 12 and 24 weeks based on both
intention-to-treat (ITT) and per-protocol (PP) populations (all p values >0.05). No significant difference was noted in
the proportion of patients attaining ACR20, ACR50, and ACR70 responses in the CinnoRA® and Humira® groups
(all p values >0.05). Further, the difference in HAQ scores and safety outcome measures between treatment
arms was not statistically significant.
Conclusion: CinnoRA® was shown to be non-inferior to Humira® in terms of efficacy at week 24 with a
comparable safety profile to the reference product.
Trial registration: IRCT.ir, IRCT2015030321315N1. Registered on 5 April 2015.
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Background
Rheumatoid arthritis (RA) is a chronic, inflammatory,
autoimmune disease of unknown pathophysiology lead-
ing to peripheral and symmetrical joint synovitis. The
primary systemic manifestations are pain, morning stiff-
ness, fatigue, and weight loss [1–3]. In progressive
forms, it may lead to cartilage damage, joint destruction,
and joint swelling resulting in impaired physical function
and premature morbidity [4–6]. RA mostly develops in
the fourth and fifth decades of life, with 80% of the cases
occurring between 35 and 50 years of age. The world-
wide prevalence of RA is about 0.5–1.0% with a female/
male ratio of 2.5:1.0 [7, 8]. Although the presence of
chronic inflammation has been proposed as a contribut-
ing factor, the exact mechanism of developing RA is still
unknown [9].
The management of RA aims primarily at improving
patients’ quality of life (QoL), achieving low disease ac-
tivity based on American College of Rheumatology
(ACR) and European League Against Rheumatism
(EULAR) criteria, and ultimately remission [1, 10]. The
treatment options for RA include non-steroidal anti-
inflammatory drugs (NSAIDs), glucocorticoids, conven-
tional synthetic disease-modifying antirheumatic drugs
(sDMARDs) and biological DMARDs (bDMARDs). RA
treatment has developed considerably in recent years,
with the early use of methotrexate (MTX) and the
addition of targeted bDMARDs in patients with an inad-
equate response to MTX [10, 11]. In fact, concomitant
use of bDMARDs and MTX has been associated with
the greatest clinical outcomes in trials and has been ap-
proved as the standard of care for patients with
moderate-to-severe disease [12]. The stage and severity
of the joint condition, the balance between possible ad-
verse effects and expected benefits, and patients’ prefer-
ences are amongst the influential factors in choosing a
DMARD. MTX is the most frequently administered
sDMARD and is used either as monotherapy or in
combination with other anti-rheumatic drugs. The early
onset of action and superior efficacy makes MTX the
synthetic agent of choice in the treatment of RA [5, 13].
Similarly, biological agents such as anti-tumor necrosis
factor-α (anti-TNF-α) monoclonal antibodies are effect-
ive in suppressing disease activity, inhibiting structural
deterioration and maintaining physical function. Adali-
mumab, a fully humanized immunoglobulin (IgG1)
monoclonal antibody is produced in genetically modified
Chinese hamster ovary cells (CHO). Adalimumab
consists of two identical heavy and two identical light
chains that bind specifically to the transmembrane TNF,
thus blocking the interaction of TNF-α with its receptor
[4, 14–16]. Adalimumab was first approved by the US
Food and Drug Administration (FDA) in December
2002 for the treatment of RA and is currently approved
for the following indications: RA, juvenile idiopathic
arthritis (JIA), psoriatic arthritis (PsA), ankylosing
spondylitis (AS), Crohn’s disease (CD), pediatric CD, ul-
cerative colitis (UC), psoriasis (PsO), pediatric plaque
PsO, hidradenitis suppurativa (HS), and non-infectious
uveitis [17, 18].
Biosimilars are biotherapeutic products that are similar
to the licensed biological reference products in terms of
quality, efficacy, and safety, but often are provided at a
lower price [19, 20]. CinnoRA® was developed by
CinnaGen Company (Alborz, Iran) as a biosimilar to the
innovator adalimumab product (Humira®). This study
aimed to evaluate the non-inferiority of test-adalimumab
(CinnoRA®) to the reference product in terms of efficacy,
tolerability, and safety in patients with active RA.
Methods
Study design
In this randomized, double-blind, non-inferiority trial,
a total of 136 patients with active RA were random-
ized in a 1:1 ratio to receive 40-mg subcutaneous in-
jections of either biosimilar adalimumab (CinnoRA®,
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CinnaGen Co., Iran) or the reference product (Humira®,
AbbVie Inc., USA) every other week along with metho-
trexate (15 mg/week), folic acid (1 mg/day), and prednisol-
one (7.5 mg/day) over a period of 24 weeks. The study
was conducted in accordance with the principles of good
clinical practice (GCP) and the declaration of Helsinki
across 10 referral hospitals in Iran. All the procedures
were approved by the Institutional Review Board (IRB)
and Ethics committees of each hospital. Patients provided
written informed consent forms before initiation of any
study-related procedure. The trial is registered in the
Iranian registry of clinical trials with the following identifi-
cation code IRCT2015030321315N1.
Patients’ demographic information was recorded at
baseline and a thorough medical examination was per-
formed. Vital signs and laboratory examinations were
taken from the patients at baseline and at the 12-week
and 24-week visits. All the injections were administered
by trained nurses at each study site. After initial screen-
ing and assessing eligibility, patients were randomized by
permuted balanced block randomization with a block
size of four. The randomization was implemented using
telephone randomization by an independent contract re-
search organization. Allocated treatments were adminis-
tered to patients based on their enrollment number.
Patients, nurses, and physicians were unaware of the size
of the blocks and the allocated treatments, and the
blinding was maintained till the end of the intervention.
Information relating to demographic characteristics,
contact history of subjects diagnosed with active tuber-
culosis (TB), medical history, and prior medications
were collected. Body weight and height were measured
and a complete physical examination was performed.
Also, vital signs including heart rate and blood pressure
were measured. Laboratory examinations, including
hematological and blood chemistry assessment, meas-
urement of rheumatoid factor, C-reactive protein (CRP),
hepatitis B surface antigen, and hepatitis C antibody,
urinalysis, and a pregnancy test in women, were per-
formed during a fasting state.
Participants
Adult subjects of each gender who met the following cri-
teria were included in this study: age between 18 and
75 years; active RA diagnosed by EULAR criteria [21];
moderate-to-severe RA for at least 6 months; lack of re-
sponse to conventional non-biologic anti-rheumatic
drugs after at least 12 months of therapy; and the ability
to read, understand, and sign the written informed con-
sent form.
Patients with any of the following criteria were ex-
cluded from the study: active or latent TB with a puri-
fied protein derivative (PPD) tuberculin test more than
5 mm in size or abnormal chest X-ray (CXR); previous
treatment with TNF inhibitors; known hypersensitivity
to human immunoglobulin proteins or other compo-
nents of adalimumab formulation; in women, pregnancy,
current nursing, or intention to become pregnant during
the study; positive serology test for hepatitis B or C or
human immunodeficiency virus antibody; ACR func-
tional class IV or wheelchair/bed bound; taking intraven-
ous antibiotics during the 8 weeks prior to screening or
receiving oral antibiotic treatment during the 2 weeks
before screening; history of serious, relapsing, or chronic
infection; hemoglobin less than 8.5 g/dl; platelet count
less than 125,000/μl; leukocyte count less than 3500/μl;
serum creatinine more than 2 mg/dl; concomitant use of
NSAIDs or more than 10 mg/day of prednisolone; re-
ceiving intravenous, intramuscular, intra-articular or oral
corticosteroids (prednisolone, more than 7.5 mg/day) in
the previous 4 weeks; previous treatment with rituximab,
azathioprine, or 6-mercaptopurine (6-MP); history of
chronic heart failure (CHF); history of myocardial
infarction (MI) or unstable angina pectoris within
12 months prior to screening; history of demyelinating
diseases or multiple sclerosis; history of malignancy
within 5 years prior to screening; and participation in
the study judged by the physician to be potentially
harmful to the patient.
Efficacy and safety assessment
The percent of patients achieving good and moderate
disease activity score (DAS)-based EULAR response was
the primary endpoint of this study. The proportion of
patients reaching ACR criteria for 20% (ACR20), 50%
(ACR50), and 70% (ACR70) improvements after 24 weeks
of treatment with adalimumab along with the disability
index of the health assessment questionnaire (HAQ),
and safety were the secondary endpoints of this study
[22, 23]. The incidence of adverse events at each visit
was recorded based on patients’ reports, vital signs,
physical examinations, and laboratory tests.
Statistical analysis
In a study conducted by Broeder et al., 89% of the pa-
tients who received adalimumab achieved EULAR re-
sponse [24]. The sample size of 64 people in each group
was estimated by a non-inferiority margin of δ = −0.18
that was based on clinical judgement with 90% power
and a 0.025 one-sided significance level. Primary efficacy
measures were evaluated using both intention-to-treat
(ITT) and per-protocol (PP) populations, while ITT
population was used for safety assessment. Data were
analyzed using Student's independent samples t test, the
Mann-Whitney U test, the normal approximation test,
Pearson’s chi-square test, and Fisher's exact test. P values
<0.05 were considered statistically significant. Data were
analyzed using Stata 11.2 software (College Station, TX,
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USA) and plotted using GraphPad prism version 6.0
(GraphPad Software, USA).
Results
A total of 216 subjects were screened across 10 hospitals
in Iran, of whom 136 patients were considered eligible
for participation in this study. Patients were enrolled in
the CinnoRA® or Humira® arms (68 subjects in each
arm) and 64 patients in each group completed the 24-
week study period. Four patients in the CinnoRA® group
withdrew from the study for the following reasons:
adverse drug reactions (ADR, n = 2), positive PPD test
(n = 1), and poor compliance (n = 1). Similarly, four pa-
tients in the Humira® group left the trial because of ADR
(n = 3) and poor compliance (n = 1). The study profile is
shown in Fig. 1.
Patients who were randomized to the CinnoRA® or
Humira® arms had comparable baseline characteristics.
The mean age of the participants in the CinnoRA® and
Humira® groups was 48.29 ± 12.72 and 47.59 ± 11.48 years,
respectively. The mean DAS in 28 joints based on
erythrocyte sedimentation rate (DAS28-ESR) was 5.51 ±
1.24 in the CinnoRA® arm and 5.47 ± 1.28 in the Humira®
arm. The baseline characteristics are summarized in
Table 1.
At week 12, the DAS28-ESR values were 2.95 ± 1.30,
and 2.96 ± 1.41 in the CinnoRA® and Humira® groups,
respectively (P value = 0.97); at week 24 the DAS28-ESR
values were 2.58 ± 1.06 in the CinnoRA® arm vs. 2.55 ±
1.14 in the Humira® group (p value = 0.88).
According to the PP population, the proportion of pa-
tients fulfilling moderate and good EULAR response cri-
teria based on the DAS28-ESR at week 12 was 42.42% and
54.55% in the CinnoRA® arm compared to 37.88% and
51.52% in the Humira® group, respectively (cumulative 12-
week good and moderate EULAR response in the PP
population 97% in the CinnoRA® vs. 89% in the Humira®
arm; p value = 0.08; CI for the difference = −0.9 to 16). At
24 weeks, 28.13% and 70.31% in the CinnoRA® vs. 31.25%
and 67.19% in the Humira® arm met the criteria for mod-
erate and good EULAR response, respectively (cumulative
24-week good and moderate EULAR response in the PP
Fig. 1 Trial profile. ITT intention-to-treat, PP per-protocol
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population 98% in the CinnoRA® vs. 98% in the Humira®
arm; p value = 1; CI for the difference = −4 to 4). Similarly,
in the ITT population, 41.18% and 36.73% achieved mod-
erate EULAR response at 12 weeks in the CinnoRA® and
Humira® arms, respectively, and 52.94% in the CinnoRA®
arm and 50.00% in the Humira® arm achieved good
EULAR response at 12 weeks (cumulative 12-week
good and moderate EULAR response in the ITT
population 94% in the CinnoRA® vs. 87% in the Humira®
arm; p value = 0.14; CI for the difference = −2 to 17). At
24 weeks, moderate EULAR response was attained in
26.47% of patients in the CinnoRA® arm compared to
29.41% in the Humira® arm. However, good EULAR re-
sponse was achieved in 66.18% of patients in the
CinnoRA® arm and 63.24% in the Humira® arm (cumula-
tive 24-week good and moderate EULAR response in the
ITT population 93% in the CinnoRA® vs. 93% in the
Humira® arm; p value = 1; CI for the difference = −9 to 9).
Based on the prespecified margin of 20%, non-inferiority
of test-adalimumab to the reference product in terms of
the proportion of patients achieving good or moderate
EULAR response was confirmed at both the 12-week and
24-week time points (Fig. 2, Table 2).
The median (IQR) HAQ scores at 12 and 24 weeks
were 0.25 (0.88) and 0.25 (0.63) in the CinnoRA® arm
vs. 0.38 (0.88) and 0.19 (0.63) in the Humira® arm, re-
spectively. The difference between treatment arms was
not statistically significant at the respective time points
(12 weeks, p value = 0.87; 24 weeks, p value = 0.48).
The proportion of patients achieving ACR20, ACR50,
and ACR70 responses at the 12-week time point were
85%, 61%, and 28% in the CinnoRA® arm compared to
respective values of 76%, 48%, and 36% in the Humira®
arm. At week 24, 92%, 77%, and 47% of the patients in
the CinnoRA® arm achieved ACR20, ACR50, and ACR70
responses, respectively, which was similar to those ob-
served in the Humira® arm (89%, 75%, and 53%, respect-
ively). No statistically significant difference was observed
between treatment arms at either the 12-week or the 24-
week time point (all p values >0.05, Fig. 3).
The incidence of adverse effects was comparable be-
tween patients who received test-adalimumab compared
to those who took the reference product. Overall, a total
of 24 patients (35.29%) in the CinnoRA® arm vs. 30
(44.12%) patients in the Humira® arm reported at least
one adverse event. The most prevalent adverse events
were local (8.82% with CinnoRA®, 17.65% with Humira®)
and respiratory (8.82% with CinnoRA®, 20.59% with
Humira®) adverse effects (Table 3).
Discussion
Randomized clinical trials demonstrating comparable ef-
ficacy, safety and tolerability of the biosimilar and innov-
ator products are absolutely necessary as well as
analytical evidence to establish similar physicochemical
and biological actions of the products. Biosimilars im-
prove the availability of more affordable products while
offering similar efficacy and safety to the reference prod-
uct [18, 25–27]. The perception of biosimilarity has been
changed over recent years, especially in rheumatology.
In September 2016, AMJEVITA™ (Amgen®, Thousand
Oaks) was approved by the FDA, as a biosimilar adali-
mumab for treatment of seven inflammatory diseases.
Similarly, Exemptia™, another adalimumab biosimilar,
was approved in India. Etanercept and infliximab biosi-
milars were also authorized in various indications. In
May 2016, Inflectra™ was approved by the European
Medicines Agency (EMA) and the FDA as an infliximab
biosimilar for all indications of the reference infliximab,
including RA, AS, PsA, PsO, CD, and UC. In the case of
etanercept, the biosimilar HD203 was recently approved
in South Korea. In addition, Samsung Bioepis’s SB4,
known as BRENZYS™ (Samsung Bioepis Co., Ltd., Korea)
received regulatory approval from the Korean Ministry
of Food and Drug Safety (MFDS), the European
Commission (EC), and the Australian Therapeutic
Goods Administration (TGA) to be used as a biosimilar
alternative to etanercept [18, 28].
In this randomized, double-blind, parallel-group, non-
inferiority study, the efficacy and safety of CinnoRA®
were compared with those of adalimumab in the
Table 1 Summary of the baseline characteristics of the patients
Variable CinnoRA® Humira® P value
Age 48.29 ± 12.72 47.59 ± 11.48 0.73
Sex, n (%)
Male 10 (14.71%) 8 (11.76%) 0.85*
Female 58 (85.29%) 60 (88.24%)
Swollen joint count, 28 joints 9.96 ± 7.39 9.46 ± 6.98 0.69
Tender joint count, 28 joints 9.46 ± 8.23 9.66 ± 7.97 0.88
Patient assessment of pain 67.21 ± 23.51 70.22 ± 21.93 0.44
Patient global assessment of
disease activity
70.15 ± 20.35 70.74 ± 22.21 0.87
Physician’s global assessment
of disease activity
68.97 ± 17.38 70.44 ± 17.68 0.63
CRP (mg/L) 21.40 ± 25.98 18.90 ± 23.90 0.57
ESR (mm/h) 32.65 ± 21.24 31.12 ± 24.01 0.69
HAQ 1.25 (1.38) 1.38 (1.13) 0.56†
DAS28-ESR 5.51 ± 1.24 5.47 ± 1.28 0.87
RF 63.76 ± 57.22 76.95 ± 65.66 0.22
Data are shown as mean ± SD and were analyzed using the independent t test
unless stated otherwise. CRP C-reactive protein, DAS28 disease activity score in 28
joints, ESR erythrocyte sedimentation rate, HAQ health assessment questionnaire,
RF rheumatoid factor. *Data were analyzed using Pearson's chi-squared test.
†Scores are shown as median (interquartile range) and were analyzed using the
Mann-Whitney U test
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treatment of adult patients with active RA. Several stud-
ies have assessed the efficacy of 40 mg adalimumab ad-
ministered subcutaneously every other week, in terms of
ACR criteria and DAS-based EULAR response. In the
study of Bombardieri et al., the efficacy of adalimumab
was evaluated in RA patients for a 12-week period. By
the end of week 12, about 60% and 33% of patients
achieved ACR20 and ACR50 responses, respectively.
Based on EULAR criteria, 76% of patients attained a
moderate response and 23% attained a good response. In
addition, 12% of patients reached clinical remission,
achieving a DAS28 less than 2.6 [29, 30]. In another
study, Huang et al. assessed the efficacy and safety of
adalimumab in combination with MTX by administrat-
ing 40 mg adalimumab every other week for 12 weeks.
The results of this multicenter, randomized, double-
blind, placebo-controlled clinical trial indicated that 57%
of patients achieved ACR20 and 32.2% of them achieved
ACR50 responses [31]. In line with previous studies, we
evaluated the percentage of patients with moderate-to-
good DAS-based EULAR response, which was our
primary outcome measure. Additionally, we compared
the number of patients reaching ACR 20, ACR50, and
ACR70 responses, along with ESR, CRP, and HAQ status.
The percentage of our patients achieving moderate and
good EULAR responses increased significantly in both the
CinnoRA® and the Humira® arms, and the difference be-
tween the two arms was not statistically significant. Fur-
ther, the percentage of patients reaching ACR20, ACR50,
and ACR70 increased significantly during the 6-month
period. In the retrospective study of Takeuchi et al. inves-
tigating the ability of adalimumab to reduce disease activ-
ity in 167 patients with RA, the mean DAS28-ESR
score decreased from 5.3 ± 1.3 at baseline to 3.5 ± 1.5
at week 52 (p < 0.0001), which is consistent with our find-
ings [32].
Furst et al. conducted a double-blind, placebo-
controlled study and assigned patients into groups re-
ceiving either adalimumab 40 mg subcutaneously every
other week or placebo. The study aimed to evaluate the
efficacy of adalimumab when given with standard anti-
rheumatic therapy over 24 weeks in patients with active
Fig. 2 Evaluation of non-inferiority of test-adalimumab to reference adalimumab in terms of the proportion of patients who met good and
moderate disease activity score in 28 joints based on erythrocyte sedimentation rate (DAS28-ESR) European League Against Rheumatism (EULAR)
response in the per-protocol (PP) population at 12 weeks, 95% CI for the difference −0.009 to 0.16 (a); the intention-to-treat (ITT) population at
12 weeks, 95% CI for the difference −0.02 to 0.17 (b); the PP population at 24 weeks, 95% CI for the difference −0.04 to 0.04 (c); and the ITT
population at 24 weeks, 95% CI for the difference −0.09 to 0.09 (d)
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RA, who were not adequately responding to such therap-
ies. Similarly, a 24-week follow-up period was considered
to evaluate the efficacy and safety of test-adalimumab in
rheumatic patients [33].
Aletaha et al. chose the 3-month time point as a crit-
ical decision point in the treatment of patients with RA.
It seems that patients who have significantly improved
by 3 months are more likely to reach their treatment tar-
get by 6 months. In fact, achieving responses at 3 months
is a good indicator of remission at 12 months, whereas
patients with poor responses at 3 months will probably
benefit from changing the treatment [34]. In agreement
with previous studies, patients in our study who had no-
ticeable improvements at 3 months also had better re-
mission status. Patients in the CinnoRA® arm responded
to treatment within a shorter period of time; however,
this difference was not statistically significant. In the
study of Burmester et al. in rheumatic patients receiving
adalimumab for approximately 5 years, the mean HAQ-
disability index score decreased in the first 6 months
and then remained steady till the end of the study [35].
Similarly, in our study the mean HAQ score decreased
significantly in both treatment arms and the difference
between the groups was not statistically significant. In fact,
as an important therapeutic goal, adalimumab improved
social and physical functions in rheumatic patients.
In the safety analyses of the study of Takeuchi et al.,
the most frequently noted adverse events during one
year of treatment with adalimumab were reactions at the
drug administration site, with a frequency of 11.40/100
patient-years [32]. Safety was evaluated based on the ad-
verse events reported by patients. All the adverse events
were summarized according to the Medical Dictionary
for Regulatory Activities system organ class (MedDRA
SOC). We did not notice any significant difference in
the incidence of injection site reactions as the most
prevalent adverse events between treatment arms, and
our findings were consistent with previous studies.
Table 2 Summary of DAS28-ESR, HAQ, and EULAR response measures
Variable Week CinnoRA® Humira® P value
DAS28-ESR 12 2.95 ± 1.30 2.96 ± 1.41 0.97*
24 2.58 ± 1.06 2.55 ± 1.14 0.88*
HAQ 12 0.25 (0.88) 0.38 (0.88) 0.87**
24 0.25 (0.63) 0.19 (0.63) 0.48**
EULAR response (PP) No response, n (%) 12 2 (3.03) 7 (10.61) 0.28***
Moderate response, n (%) 28 (42.42) 25 (37.88)
Good response, n (%) 36 (54.55) 34 (51.52)
No response, n (%) 24 1 (1.56) 1 (1.56) 0.92***
Moderate response, n (%) 18 (28.13) 20 (31.25)
Good response, n (%) 45 (70.31) 43 (67.19)
EULAR response (ITT) No response, n (%) 12 4 (5.88) 9 (13.24) 0.37***
Moderate response, n (%) 28 (41.18) 25 (36.76)
Good response, n (%) 36 (52.94) 34 (50.00)
No response, n (%) 24 5 (7.35) 5 (7.35) 0.96***
Moderate response, n (%) 18 (26.47) 20 (29.41)
Good response, n (%) 45 (66.18) 43 (63.24)
DAS28-ESR disease activity score in 28 joints based on erythrocyte sedimentation rate, HAQ health assessment questionnaire, EULAR European League Against
Rheumatism, PP per-protocol, ITT intention-to-treat. *Data are shown as mean ± SD and were analyzed using the independent samples t test. **Scores are shown
as median (interquartile range) and were analyzed using the Mann-Whitney U test. ***Data were analyzed using Fisher's exact test
Fig. 3 The proportion of patients achieving American College of
Rheumatology 20%, 50% or 70% response (ACR20, ACR50, or ACR70)
following treatment with test or reference adalimumab at 12
and 24 weeks
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Despite having a negative PPD test at the beginning of the
study, one of the patients had a positive PPD test 8 weeks
later that was probably due to close contact with a patient
infected with TB close to the time of study enrollment.
Conclusion
Based on our findings, CinnoRA®, as a biosimilar adali-
mumab, was shown to be non-inferior to Humira® in the
treatment of adult patients with active RA.
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Organ systems Type CinnoRA® Humira®
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Dermatologic Hives 2 (2.94) 5 (7.35)
Swelling
Rash
Local Inject site react., erythema 6 (8.82) 12 (17.65)
Inject site react., itching
Inject site react., hemorrhage
Inject site react., swelling
Inject site react., pain
Respiratory Sinusitis 6 (8.82) 14 (20.59)
Flu-like syndrome
Difficulty breathing
Respiratory infection
Gastrointestinal Nausea 5 (7.35) 2 (2.94)
Abdominal pain
Central nervous system Headache 4 (5.88) 4 (5.88)
Renal Urinary tract infection 1 (1.47) 1 (1.47)
Neuromuscular Back pain 1 (1.47) 2 (2.94)
Other Other 11 (16.18) 6 (8.82)
*Data were analyzed using the Pearson chi-squared test (p value = 0.29).
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